130369-33-4

Usage

Uses

Used in Organic Synthesis:
(3,3-dimethoxycyclobutane-1,1-diyl)dimethanol is utilized as a building block in the formation of more complex organic molecules, owing to its unique structural properties and reactivity.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, (3,3-dimethoxycyclobutane-1,1-diyl)dimethanol is employed as a valuable intermediate in the synthesis of various organic compounds, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
(3,3-dimethoxycyclobutane-1,1-diyl)dimethanol is used as a key component in the creation of agrochemicals, potentially enhancing the effectiveness of pesticides and other agricultural chemicals.
Used in Materials Science:
Within the materials science field, (3,3-dimethoxycyclobutane-1,1-diyl)dimethanol is leveraged for its potential applications in developing new materials with improved properties, such as enhanced stability or specific functionalities.
Overall, (3,3-dimethoxycyclobutane-1,1-diyl)dimethanol's versatility and importance in organic chemistry make it a crucial compound for various industries, including pharmaceutical, agrochemical, and materials science, where it plays a significant role in the synthesis of complex organic molecules and the development of innovative products.

Upstream product

• 115118-68-8 3,3-dimethoxycyclobutane-1,1-dicarboxylic acid diisopropyl ester 
• 115118-67-7 diethyl 3,3-dimethoxycyclobutane-1,1-dicarboxylate 

Downstream Products

• 1023815-74-8 (3,3-dimethoxycyclobutane-1,1-diyl)bis(methylene) bis(4-methylbenzenesulfonate) 
• 130368-81-9 9-<3,3-bis(hydroxymethyl)cyclobut-1-yl>guanine 
• 131853-47-9 9-<3,3-bis(hydroxymethyl)cyclobut-1-yl>adenine 
• 131853-56-0 9-<3,3-bis(benzyloxymethyl)cyclobut-1-yl>guanine 
• 131853-55-9 2-amino-6-chloro-9-<3,3-bis(benzyloxymethyl)cyclobut-1-yl>-9H-purine 
• 131853-53-7 2,5-diamino-6-chloro-4-<<3,3-bis(benzyloxymethyl)cyclobut-1-yl>amino>pyrimidine 
• 131853-57-1 9-<3,3-bis(benzyloxymethyl)cyclobut-1-yl>adenine 
• 131853-54-8 6-chloro-9-<3,3-bis(benzyloxymethyl)cyclobut-1-yl>-9H-purine 
• 131853-52-6 5-amino-6-chloro-4-<<3,3-bis(benzyloxymethyl)cyclobut-1-yl>amino>pyrimidine 
• 131853-58-2 9-<3-benzyloxymethyl-3-hydroxymethylcyclobut-1-yl>adenine 
• 131853-51-5 3,3-bis(benzyloxymethyl)cyclobutanone oxime 
• 131853-50-4 3,3-bis(benzyloxymethyl)cyclobutanone 
• 131853-48-0 1-amino-3,3-bis(benzyloxymethyl)cyclobutane 
• 305819-04-9 C₄₂H₄₄O₉S₂ 

Relevant academic research and scientific papers

NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein said compound of formula (I) comprises at least one covalently bound -ONO2 or -ONO moiety and at most four covalently bound -ONO2 or -ONO moieties, and wherein AR, R1, X, R3 and R4 are as defined in claim 1; and pharmaceutical compositions thereof, and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-human mammal.

SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR

Disclosed in the present invention are an indoleamine-2,3-dioxygenase inhibitor and a preparation method therefor. The inhibitor of the present invention has a structure as represented by general formula (I), wherein the definitions of Ar, E, Y, X, V, D, W, B, ring A and ring B are as shown in the description and claims. Also disclosed in the present invention is a preparation method for the inhibitor. The compound of general formula (I) of the present invention can be used as an indoleamine-2,3-dioxygenase inhibitor for preparing a medicament for preventing and/or treating indoleamine-2,3-dioxygenase-mediated diseases.

Synthesis of 2-azaspiro[3.3]heptane-derived amino acids: Ornitine and GABA analogues

Synthesis of 6-amino-2-azaspiro[3.3]heptane-6-carboxylic acid and 2-azaspiro[3.3]heptane-6-carboxylic acid was performed. Both four-membered rings in the spirocyclic scaffold were constructed by subsequent ring closure of corresponding 1,3-bis-electrophil

AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS

The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

Synthesis of conformationally restricted glutamic acid analogs based on the spiro[3.3]heptane scaffold

A library of isomeric glutamic acid analogs based on the spiro[3.3]heptane skeleton is designed. Two members of the library, (R)- and (S)-2-amino-spiro[3.3]heptane-2,6-dicarboxylic acid hydrochlorides, were synthesized. The stereochemistry of the synthesi

Conformationally locked nucleosides. Synthesis of 3(R,S)-(adenin-9-y1)-1- and 3(R,S)-(cytosin-1-y1)-1-hydroxymethylbicyclo[2,1,1]hexanes

3,3-Di(isopropoxycarbonyl)-1,1-dimethoxycyclobutane (1) was converted, in multi-steps, to 3-(1,3-dithiacyclohex-2-yl)-1,1-di(p-tosyloxymethyl)cyclobutane (7), which was subjected to a butyllithium-mediated cyclization to give the bicyclo[2,1,1]hexane ring system 8. Further transformations afforded 1-(t-butyldimethylsilyloxymethyl)-3(R,S)-hydroxybicyclo[2,1,1]hexanes (11), which were condensed with 6-chloropurine and 4-acetylcytosine via Mitsunobu reactions to give, after further treatment, 3(R,S)-(adenin-9-yl)- and 3(R,S)-(cytosin-1-yl)-1-hydroxymethylbicyclo[2,1,1]hexanes (14 and 17), respectively. (C) 2000 Elsevier Science Ltd.